InterMune (ITMN -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara...
InterMune (ITMN -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara Therapeutics International for $55M in cash plus a two-year royalty stream. The company had stopped active development for Actimmune several years ago, preferring to focus its efforts on other R&D operations such as its Pirfenidone treatment for idiopathic pulmonary fibrosis.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs